Human iPSC-derived MSCs from aged individuals acquire a rejuvenation signature
The use of primary mesenchymal stem cells (MSC) is fraught with ageing-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (iPSC) -derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these ageing-associated drawbacks. The importance of this concept is manifested by the successful Phase 1 clinical trial for the treatment of GvHD by Cynata Therapeutics and the National Health Service- ROYAUME-UNI; a Phase 2 trial is planned for 2019. Note, this trial is independent of the work carried out by Spitzhorn et al.-described below.
Vous souhaitez savoir si les programmes cliniques actuels, développements de la recherche, ou des approches thérapeutiques émergentes peuvent être pertinentes à votre situation?
Informations pédagogiques et de recherche uniquement. Les décisions médicales individuelles doivent être prises en consultation avec des professionnels de santé qualifiés..
